Lawrence Steinman

Publication Details

  • REPEATED TREATMENT WITH CHIMERIC ANTI-CD4 ANTIBODY IN MULTIPLE-SCLEROSIS ANNALS OF NEUROLOGY Lindsey, J. W., Hodgkinson, S., Mehta, R., Mitchell, D., ENZMANN, D., Steinman, L. 1994; 36 (2): 183-189


    We treated 21 multiple sclerosis patients with two to four doses of cM-T412, a chimeric monoclonal antibody against the CD4 antigen found on helper/inducer T lymphocytes. The mean number (+/- standard error) of circulating CD4 lymphocytes decreased from 888 (+/- 81) cells/mm3 at baseline to 246 (+/- 18) after treatment. At 1 year after the last treatment, the CD4 count had recovered to only 335 (+/- 32). The antibody had no effect on CD8 lymphocytes, B lymphocytes, or other leukocytes. Side effects were minimal. Despite the prolonged depletion of CD4 lymphocytes, no opportunistic infections occurred. Only 1 patient had a possible allergic reaction. Most patients were clinically stable, but a few progressed. We conclude that repeated treatment with cM-T412 is effective in reducing the number of circulating CD4 lymphocytes and has no limiting side effects.

    View details for Web of Science ID A1994PB26000009

    View details for PubMedID 8053654

Stanford Medicine Resources:

Footer Links: